CD8A and neoplasm: Since anti-PD-1 antibody used for the treatment was a rat IgG2a subclass, anti-rat IgG2a antibody was used for the detection of binding of anti-PD-1 antibody on the tumor-infiltrating CD3+ CD8+ T cells.